Parkman Healthcare Partners LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Parkman Healthcare Partners LLC
CRD #300701
SEC #801-114849
CIK #0001777015
AUM 1,744.0 M (2026-03-27)
Employees 12 (67% Investors, 0% Brokers)
Fees
Minimum
Phone203-516-3690
Address700 Canal Street
Stamford, CT 06902
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
18001440108072036002010201520212027
Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure]
Item 5 – Fees and Compensation (Continued)

    Account, the Adviser is compensated either through a pre-negotiated monthly fee or on a
    quarterly basis in arrears. Additionally, the Managed Accounts pay the Adviser an annual
    performance fee, equal to a set percentage of net appreciation of the assets held by such
    accounts. Such fees are generally paid by the owners of the applicable accounts and not
    deducted from the assets of the Managed Account.

B. Fees are generally deducted by the Adviser from the Fund. Fees are not automatically
   deducted from the Managed Accounts and are billed based on the terms of the relevant
   investment advisory agreement that was negotiated with the applicable Managed Account.

C. Any other types of fees or expenses Clients may pay in connection with Parkman’s advisory
   services will depend on the respective Client’s advisory agreement. The Clients may incur
   brokerage and other transaction costs. The Client will generally bear all expenses relating to
   its ongoing structure and operation (including direct expenses of the Client) pursuant to the
   terms of its Offering Documents. Clients may incur expenses relating to the organization,
   maintenance, and operation of the Client accounts including, but not limited to, registered
   agent fees, costs related to compliance, regulatory and AML matters, costs associated with
   gaining access to non-U.S. markets, all direct trading expenses, including but not limited to,
   execution and clearing commissions, transaction charges, ticket charges, fees and expenses
   incurred in the borrowing and lending of securities, custodian and trustee fees, bank service
   fees, transfer taxes, withholding taxes, administrative fees (including fees paid to the Client’s
   administrator) accounting, tax preparation and audit fees, fees paid to third-parties retained
   by the Client related to the delivery of the trade file, and other fees and expenses related to
   the purchase, sale or other disposition of assets. Please see the disclosures in Item 12 as it
   relates to Parkman’s brokerage activities.

D. As stated above, the Management Fees are deducted directly from the Fund and paid quarterly
   in advance. The Management Fee is prorated for any period that is less than one full quarter
   for investments made by new or existing investors and refunded on a prorated basis upon
   withdrawal or redemption from the Fund prior to quarter-end.

    As described in detail in the relevant investment advisory agreements for each Managed
    Account, the Managed Accounts pay Parkman management fees either monthly or quarterly
    in arrears based on the Account’s percentage of the Adviser’s assets under management. In
    the event of the termination of a Managed Account’s agreement, the Managed Account shall
    pay prorated management fee through the end of the foregoing notice period.

E. Other than as described above, neither Parkman nor any of its supervised persons receive any
   additional compensation from the sale of securities or other investment products.
Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure]
Item 7 - Types of Clients

As mentioned in Item 4, Parkman provides investment advisory services to its Clients based on
the investment objectives and strategies described in the Offering Documents.

Admission as an Investor in the Fund is not open to the general public. The Fund is not intended as
a complete investment program and is designed only for persons who are able to bear the economic
risk of the loss of their entire investment in the Fund and who have a limited need for liquidity in
their investments. Fund interests will generally be sold only to qualified investors who are
“accredited investors” under Regulation D of the Securities Act of 1933, as amended, and “qualified
purchasers” as such term is defined in Section 2(a)(51) of the Investment Company Act.

The minimum initial investment in the Fund is $1,000,000, subject to reduction in the sole discretion
of the General Partner. In general, the Fund will accept investments monthly. Investments will be
made in cash or, in the General Partner’s sole discretion, in securities or partly in cash and partly in
securities.

The General Partner may admit additional or substitute general partners (i) as of the beginning of
any calendar quarter upon 60 calendar days’ prior written notice to all Investors, (ii) at any time
with the consent of the majority in interest of the Investors, or (iii) at any time if such additional
or substitute general partners are affiliates of the General Partner or its principals or an estate
planning vehicle established for the benefit of a family member.
Sector Form 13F Holdings Value ($M)
Stryker Corp 50.9
Dexcom Inc 43.3
Insulet Corp 32.9
Lilly Eli & Co 31.8
PTC Therapeutics Inc 29.4
Xenon Pharmaceuticals Inc 28.9
Boston Scientific Corp 28.2
CVS Caremark Corp 27.8
Arcus Biosciences Inc 26.1
Livanova PLC 25.7
View All
Holdings by Sector ($M)
110088066044022002019202120242027
Type Form D Funds Date Sold AUM
PE Parkman Venture Partners SPV I LP [2023-03-27] 9.2 M 4.1 M
Offered $9,250,000 · Filed 2022-05-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose
HF Parkman HP Master Fund LP [2019-07-02] 64.5 M 718.9 M
Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 7 1,744.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 7 1,744.0
By Discretionary
Discretionary 7 1,744.0
Non-Discretionary 0 0.0
Total 7 1,744.0
By Non-United States Persons
Non-United States Persons 1,744.0
United States Persons 0.0
Total 7 1,744.0
Form D Directors Role # Filings # Firms 2011 - 2026
Parkman Healthcare Partners LLC Executive Officer 3 2
Parkman Venture Partners GP LLC Executive Officer 1 1
Parkman HP Fund GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001777015]
3 [0001777015]
4 [0001777015]
SC 13G [0001777015]
Form 13D/13G Filer Form 13D/13G Subject Filed
Parkman Healthcare Partners LLC InspireMD Inc [2025-11-14]
Parkman Healthcare Partners LLC Plus Therapeutics Inc [2022-02-04]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300SDS6C71DAN3T72
Form 3/4/5 Subject 2011 - 2026
Martinez Gregory
Parkman Healthcare Partners LLC
Spruce Biosciences Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Sell 232 $19.33 4,485
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Sell 25 $17.46 436
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Buy 256 $17.91 4,585
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Sell 232 $19.33 4,485
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Buy 256 $17.91 4,585
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
2025-10-06 Sell 25 $17.46 436
Comparable Firms State AUM
Tensile Capital Management LP
CA 1,796.0 M
Morgan Creek Capital Management LLC
NC 1,790.2 M
QVT Financial LP
NY 1,786.7 M
Alta Park Capital LP
CA 1,779.6 M
Great Point Partners LLC
CT 1,777.1 M
OFS Capital Management LLC
IL 1,760.0 M
RCF Management LLC
CO 1,757.0 M
Long Path Partners LP
CT 1,732.8 M
Galaxy Digital Capital Management LP
NY 1,723.0 M
Wexford Capital LP
FL 1,720.5 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com